The clinical and histological diagnosis of sarcomas is often very difficult. The identification of chromosomal and molecular anomalies, such as amplifications, deletions or fusion genes is a powerful help for establishing a correct diagnosis of sarcomas and their benign counterparts. However, the cost of the cytogenetic and molecular techniques for the detection of these alterations is often a limitation to their use. The aim of our study is to evaluate the direct cost of the molecular techniques in comparison to the cost that would be generated by an appropriate therapy and care management of the patient in case of an erroneous diagnosis.
Study Type
OBSERVATIONAL
Enrollment
350
Departement de Pathologie de l'Institut Bergonié
Bordeaux, France
Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Lille
Lille, France
Département d'Anantomie et de Cytologie Pathologie, Centre Léon Berard
Lyon, France
Laboratoire de Génétique des Tumeurs Solides
Nice, France
Institut Curie
Paris, France
Service d'Anatomo-Pathologie, Centre Paul Strauss
Strasbourg, France
Unité de Biologie Moléculaire, CHU de Hautepierre
Strasbourg, France
Département de biologie et de pathologie médicales, Institut Gustave roussy
Villejuif, France
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.